Women's Health Preclinical Deal Benchmarks — Ex-US (2026)
Median upfront of $17M with total deal values reaching $363M in Ex-US territory.
Median Upfront
$17M
Total Deal Value
$234M
Royalty Range
2.7%–6.2%
Territory Multiplier
0.45x
Understanding Women's Health Deal Benchmarks at Preclinical
Preclinical Women's Health licensing deals in Ex-US territory command a median upfront payment of $17M, with values ranging from $6M at the low end to $30M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the women's health therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Full Benchmark Data
Full Benchmark Table
Low, median, and high ranges for upfront payments, total deal values, and royalty rates.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Comparable Deals
See All Comparable Deals
View 0 comparable Women's Health transactions with upfront payments, total values, and deal structures.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Preclinical Women's Health deals in Ex-US territory?
More Expert Insights
Territory impact analysis, royalty negotiation strategies, and deal structure guidance.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Related Benchmarks
$42M upfront
Women's Health · Phase 1 · Ex-US
$147M upfront
Women's Health · Phase 2 · Ex-US
$389M upfront
Women's Health · Phase 3 · Ex-US
$1.1B upfront
Women's Health · Approved · Ex-US
$15M upfront
Oncology · Preclinical · Ex-US
$15M upfront
Neurology/CNS · Preclinical · Ex-US
$32M upfront
Immunology · Preclinical · Ex-US
$35M upfront
Metabolic/Obesity · Preclinical · Ex-US
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open Deal CalculatorCite This Data
Ambrosia Ventures. (2026). Women's Health Preclinical Deal Benchmarks — Ex-US (2026). Retrieved from https://calculator.ambrosiaventures.co/data/womens-health-preclinical-deals-ex-us
<a href="https://calculator.ambrosiaventures.co/data/womens-health-preclinical-deals-ex-us">Women's Health Preclinical Deal Benchmarks — Ex-US (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://calculator.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=womensHealth&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,900+ verified biopharma transactions. Updated monthly.